Transforming Healthcare Ecosystems with Artificial Intelligence

by GeneOnline
Share To

Two sessions over two days devoted entirely to AI

Artificial Intelligence (AI) is the new buzzword in biomedicine, and for good reason. With the potential to drastically reduce the time and cost burdens of drug development, the biggest names in Big Pharma are already utilizing this powerful tool. AI is increasingly important in today’s ‘smart’ healthcare settings; assisting in hospital admission triage and patient management, ‘viewing’ and analyze medial images to detect breast and other cancers, and identifying disease biomarkers for conditions such as Alzheimer’s. A vital tool in the pandemic era, AI has proven its worth in time-critical case tracking assignments and other epidemiological tasks.

A reflection of its importance, BIO Asia–Taiwan 2020 has dedicated two sessions over two days entirely to AI, with a twelve international speakers presenting the latest advances, case studies and future application scenarios for this exciting new technology.

Don’t miss Leo Anthony Celi, Principal Research Scientist, Massachusetts Institute of Technology, with his presentation ‘Battling the Pandemic with Open Science and Cross-Disciplinary Collaboration’; Faisal Khan of AstraZeneca with his talk ‘How to Apply AI to Different Stages of Drug Development’; and Joris Van Dam and Stephane Wolf of Novartis with his presentation ‘Why and How Pharma Use AI in Digital Therapeutics Platform’. Catch these and more AI-focused presentations and panel discussions at Sessions 7 and 14, BIO Asia–Taiwan 2020.


© All rights reserved. Collaborate with us:
Related Post
Advancing Healthcare Accessibility and Sustainable Development
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
AI-Designed Antibodies: A Revolution in Antibody Drug Discovery
APAC Leading the Industry in Adoptive Cell Therapy – Trials, Economic Growth, and Pioneering Companies
Taiwan’s Biotech and Pharma Delegation: Innovations Take Center Stage at BIO 2024
Breaking Ground in Alzheimer’s with 10 Cutting-Edge Treatments Paving the Way in 2024
Merck Buys EyeBio for $3B and Shares Global Policy Perspectives During BIO in San Diego
Johnson & Johnson’s Bispecific Antibodies for Atopic Dermatitis and Talks of Biotech Partnerships at BIO 2024
Merck’s KEYNOTE-522 Success; BMS Licenses PRX019, Prothena Gets $80M
SINBON and MAKALOT partner to drive cross-industry textile wearable adoption
Scroll to Top